With companies striving to push their drugs and diagnostic technologies for several oncological indications, the competition in the global epigenetics drugs and diagnostics technologies market is likely to intensify over the next couple of years, says Transparency Market Research (TMR) in a research report. The global market for epigenetics drugs and diagnostic technologies is at present dominated by a few leading companies, thus it is oligopolistic in nature. To establish a stable position in the market, the companies are focusing on introducing differentiated products for specific targeted treatment. The three leading players in the market, Celgene, Eisai, and Merck, accounted 100% of the share of the global epigenetics drugs and diagnostics technologies market in 2011.
The global market for epigenetics drugs and diagnostic technologies market is expected to register significant growth during the forecast period. The market is projected to rise to a valuation of US$5,690.0 mn by the end of 2018.
DNA Methylation to Contribute Maximum towards Revenue
Based on type, the global epigenetics drugs and diagnostic technologies market is bifurcated into DNA methylation and chromatin immunoprecipitation (ChIP). Among these two, DNA methylation emerged as the leading segment in 2015 with a market US$586.1 mn. It is projected to reach a valuation of US$967.3 mn by the end of 2018. In this process, the methyl group is transfused into the cytosine residue through DNA methyltransferases within the promoter areas. Cancer is a prominent disease which is associated with a hampered epigenetic mechanism. Owing to the inactivation of a tumor suppressor gene during a cancerous stage, the proliferation of a tumor is enhanced. As a result of this, the companies are introducing several DNA methylation detection technologies to diagnose the causative agent. The primary reason behind the rising adoption of this technology is the burgeoning adoption of next generation sequence analysis and ongoing technological advancements.
Region-wise, North America held a leading position in the global epigenetic drugs and diagnostic technologies market in 2011. It is estimated to account for a share of 41% by the end of 2018. The growth of the market in this region is due to the launch of new technologies, therapies, and drugs in this region. Oncology and other non-oncology conditions are related to epigenetics. The growth of the epigenetics drugs and diagnostic technologies market is supported by the increasing incidences of cancer in North America. According to a TMR analyst, “The demand for selective drugs such as Zolinza, Dacogen, Istodax, and Vidaza is expected to rise in the region owing to the need for targeted therapy.” The Canadian government has further starting extensively investing in research as development projects for the development of new drugs, thus aiding the growth of the epigenetics drugs and diagnostic technologies market in North America.
Burgeoning Demand for Oncology and Non-Oncology Conditions Treatment to Bolster Market Growth
One of the primary causes of death across the world is cancer. Cancer causes 13% of the total deaths in the world. According to a study conducted by the World Health Organization, it has been projected that the total number of deaths caused by cancer is will rise by 45% from 2007 to 2030. Likewise, epigenetics drugs and diagnostic technologies also find applications in the treatment of diseases of the central nervous systems. The development of innovative drugs and growing applications of epigenetic drugs is expected to further enhance the growth of the global epigenetics drugs and diagnostic technologies market. Huge investments from government and non-government organizations and medical organizations are also likely to provide lucrative growth prospects to manufacturers.
This review is based on a Transparency Market Research report titled, “Epigenetics Drugs and Diagnostic Technologies Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2012-2018.”
The global epigenetics drugs and diagnostic technologies market is segmented into the following categories:
- Epigenetics Drugs Market, by Mechanism of Action
- DNMT Inhibitors
- Azacitidine (Vidaza)
- Decitabine (Dacogen)
- HDAC Inhibitors
- Vorinostat (Zolinza)
- Romidepsin (Istodax)
- DNMT Inhibitors
- Epigenetics Diagnostic Technologies Market, by Types
- DNA Methylation
- Chromatin Immunoprecipitation (ChIP) Technology
- Epigenetics Technologies Market, by Geography
- North America
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
USA - Canada Toll Free: 866-552-3453
7 of 10 large enterprizes view our ToC to take the right decision.View Report ToC